http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Jul 2026 08:25:48 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Lowered+to+%2440+at+Morgan+Stanley/26798693.html Morgan Stanley analyst Judah Frommer lowered the price target on Celldex Therapeutics (NASDAQ: CLDX) to $40.00 (from $44.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Lowered+to+%2440+at+Morgan+Stanley/26798693.html Wed, 22 Jul 2026 08:25:48 -0400 CLDX http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Lowered+to+%2460+at+Canaccord/26797843.html (Updated - July 22, 2026 7:41 AM EDT) <p>Canaccord analyst Ed Nash lowered the price target on Celldex Therapeutics (NASDAQ: CLDX) to $60.00 (from $62.00) while maintaining a Buy rating.</p><p>The analyst commented: "Today after the market close, Celldex reported that the Phase II study for barzolvolimab in PN missed on the primary and key secondary efficacy endpoints with no difference demonstrated in the treatment group vs. PBO. The company is discontinuing the PN program. To reflect this update, we have zeroed out the PN program from our valuation and are lowing our 12-month PT from the prior $62 to $60. We http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Lowered+to+%2460+at+Canaccord/26797843.html Wed, 22 Jul 2026 07:41:24 -0400 CLDX http://www.streetinsider.com/Analyst+Comments/Celldex+Therapeutics+%28CLDX%29+PT+Lowered+to+%2460+at+Canaccord/26797843.html (Updated - July 22, 2026 7:41 AM EDT) <p>Canaccord analyst Ed Nash lowered the price target on Celldex Therapeutics (NASDAQ: CLDX) to $60.00 (from $62.00) while maintaining a Buy rating.</p><p>The analyst commented: "Today after the market close, Celldex reported that the Phase II study for barzolvolimab in PN missed on the primary and key secondary efficacy endpoints with no difference demonstrated in the treatment group vs. PBO. The company is discontinuing the PN program. To reflect this update, we have zeroed out the PN program from our valuation and are lowing our 12-month PT from the prior $62 to $60. We http://www.streetinsider.com/Analyst+Comments/Celldex+Therapeutics+%28CLDX%29+PT+Lowered+to+%2460+at+Canaccord/26797843.html Wed, 22 Jul 2026 07:41:24 -0400 CLDX http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Lowered+to+%2461+at+Cantor+Fitzgerald/26797956.html Cantor Fitzgerald analyst Kristen Kluska lowered the price target on Celldex Therapeutics (NASDAQ: CLDX) to $61.00 (from $67.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Lowered+to+%2461+at+Cantor+Fitzgerald/26797956.html Wed, 22 Jul 2026 06:59:45 -0400 CLDX http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Lowered+to+%2448+at+Wells+Fargo/26797744.html Wells Fargo analyst Derek Archila lowered the price target on Celldex Therapeutics (NASDAQ: CLDX) to $48.00 (from $54.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Lowered+to+%2448+at+Wells+Fargo/26797744.html Wed, 22 Jul 2026 06:26:46 -0400 CLDX http://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html <p><strong>After-Hours Stock Movers:</strong></p><p><strong>Super Micro Computer (NASDAQ: SMCI)</strong></p><p>Supermicro shares rocketed 20% higher following a bullish preliminary Q4 fiscal 2026 update. While fourth-quarter revenue is expected near the low end of its $11.0–$12.5 billion guidance, GAAP and non-GAAP gross margins exploded to 15%–17% (nearly doubling the guided 8.2%–8.4%) due to a favorable product and customer mix. Furthermore, record demand drove Q4 new orders above $60 billion, lifting server peers Dell Technologies (+5%) and Hewlett Packard Enterprise (+4.5%) in sympathy.</p><p><strong>Oklo Inc. (NYSE: OKLO) & X-Energy (NASDAQ: XE)</strong></p><p>Nuclear energy developers Oklo (+8%) and X-Energy (+12%) surged following reports that both companies are joining a http://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html Tue, 21 Jul 2026 16:37:16 -0400 ALK CLDX OKLO PEGA SMCI XE http://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html <p><strong>After-Hours Stock Movers:</strong></p><p><strong>Super Micro Computer (NASDAQ: SMCI)</strong></p><p>Supermicro shares rocketed 20% higher following a bullish preliminary Q4 fiscal 2026 update. While fourth-quarter revenue is expected near the low end of its $11.0–$12.5 billion guidance, GAAP and non-GAAP gross margins exploded to 15%–17% (nearly doubling the guided 8.2%–8.4%) due to a favorable product and customer mix. Furthermore, record demand drove Q4 new orders above $60 billion, lifting server peers Dell Technologies (+5%) and Hewlett Packard Enterprise (+4.5%) in sympathy.</p><p><strong>Oklo Inc. (NYSE: OKLO) & X-Energy (NASDAQ: XE)</strong></p><p>Nuclear energy developers Oklo (+8%) and X-Energy (+12%) surged following reports that both companies are joining a http://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html Tue, 21 Jul 2026 16:37:16 -0400 ALK CLDX OKLO PEGA SMCI XE http://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html <p><strong>After-Hours Stock Movers:</strong></p><p><strong>Super Micro Computer (NASDAQ: SMCI)</strong></p><p>Supermicro shares rocketed 20% higher following a bullish preliminary Q4 fiscal 2026 update. While fourth-quarter revenue is expected near the low end of its $11.0–$12.5 billion guidance, GAAP and non-GAAP gross margins exploded to 15%–17% (nearly doubling the guided 8.2%–8.4%) due to a favorable product and customer mix. Furthermore, record demand drove Q4 new orders above $60 billion, lifting server peers Dell Technologies (+5%) and Hewlett Packard Enterprise (+4.5%) in sympathy.</p><p><strong>Oklo Inc. (NYSE: OKLO) & X-Energy (NASDAQ: XE)</strong></p><p>Nuclear energy developers Oklo (+8%) and X-Energy (+12%) surged following reports that both companies are joining a http://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html Tue, 21 Jul 2026 16:37:16 -0400 ALK CLDX OKLO PEGA SMCI XE http://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html <p><strong>After-Hours Stock Movers:</strong></p><p><strong>Super Micro Computer (NASDAQ: SMCI)</strong></p><p>Supermicro shares rocketed 20% higher following a bullish preliminary Q4 fiscal 2026 update. While fourth-quarter revenue is expected near the low end of its $11.0–$12.5 billion guidance, GAAP and non-GAAP gross margins exploded to 15%–17% (nearly doubling the guided 8.2%–8.4%) due to a favorable product and customer mix. Furthermore, record demand drove Q4 new orders above $60 billion, lifting server peers Dell Technologies (+5%) and Hewlett Packard Enterprise (+4.5%) in sympathy.</p><p><strong>Oklo Inc. (NYSE: OKLO) & X-Energy (NASDAQ: XE)</strong></p><p>Nuclear energy developers Oklo (+8%) and X-Energy (+12%) surged following reports that both companies are joining a http://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html Tue, 21 Jul 2026 16:37:16 -0400 ALK CLDX OKLO PEGA SMCI XE http://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html <p><strong>After-Hours Stock Movers:</strong></p><p><strong>Super Micro Computer (NASDAQ: SMCI)</strong></p><p>Supermicro shares rocketed 20% higher following a bullish preliminary Q4 fiscal 2026 update. While fourth-quarter revenue is expected near the low end of its $11.0–$12.5 billion guidance, GAAP and non-GAAP gross margins exploded to 15%–17% (nearly doubling the guided 8.2%–8.4%) due to a favorable product and customer mix. Furthermore, record demand drove Q4 new orders above $60 billion, lifting server peers Dell Technologies (+5%) and Hewlett Packard Enterprise (+4.5%) in sympathy.</p><p><strong>Oklo Inc. (NYSE: OKLO) & X-Energy (NASDAQ: XE)</strong></p><p>Nuclear energy developers Oklo (+8%) and X-Energy (+12%) surged following reports that both companies are joining a http://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html Tue, 21 Jul 2026 16:37:16 -0400 ALK CLDX OKLO PEGA SMCI XE http://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html <p><strong>After-Hours Stock Movers:</strong></p><p><strong>Super Micro Computer (NASDAQ: SMCI)</strong></p><p>Supermicro shares rocketed 20% higher following a bullish preliminary Q4 fiscal 2026 update. While fourth-quarter revenue is expected near the low end of its $11.0–$12.5 billion guidance, GAAP and non-GAAP gross margins exploded to 15%–17% (nearly doubling the guided 8.2%–8.4%) due to a favorable product and customer mix. Furthermore, record demand drove Q4 new orders above $60 billion, lifting server peers Dell Technologies (+5%) and Hewlett Packard Enterprise (+4.5%) in sympathy.</p><p><strong>Oklo Inc. (NYSE: OKLO) & X-Energy (NASDAQ: XE)</strong></p><p>Nuclear energy developers Oklo (+8%) and X-Energy (+12%) surged following reports that both companies are joining a http://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html Tue, 21 Jul 2026 16:37:16 -0400 ALK CLDX OKLO PEGA SMCI XE http://www.streetinsider.com/Hot+List/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html <p><strong>After-Hours Stock Movers:</strong></p><p><strong>Super Micro Computer (NASDAQ: SMCI)</strong></p><p>Supermicro shares rocketed 20% higher following a bullish preliminary Q4 fiscal 2026 update. While fourth-quarter revenue is expected near the low end of its $11.0–$12.5 billion guidance, GAAP and non-GAAP gross margins exploded to 15%–17% (nearly doubling the guided 8.2%–8.4%) due to a favorable product and customer mix. Furthermore, record demand drove Q4 new orders above $60 billion, lifting server peers Dell Technologies (+5%) and Hewlett Packard Enterprise (+4.5%) in sympathy.</p><p><strong>Oklo Inc. (NYSE: OKLO) & X-Energy (NASDAQ: XE)</strong></p><p>Nuclear energy developers Oklo (+8%) and X-Energy (+12%) surged following reports that both companies are joining a http://www.streetinsider.com/Hot+List/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html Tue, 21 Jul 2026 16:37:16 -0400 ALK CLDX OKLO PEGA SMCI XE http://www.streetinsider.com/Hot+List/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html <p><strong>After-Hours Stock Movers:</strong></p><p><strong>Super Micro Computer (NASDAQ: SMCI)</strong></p><p>Supermicro shares rocketed 20% higher following a bullish preliminary Q4 fiscal 2026 update. While fourth-quarter revenue is expected near the low end of its $11.0–$12.5 billion guidance, GAAP and non-GAAP gross margins exploded to 15%–17% (nearly doubling the guided 8.2%–8.4%) due to a favorable product and customer mix. Furthermore, record demand drove Q4 new orders above $60 billion, lifting server peers Dell Technologies (+5%) and Hewlett Packard Enterprise (+4.5%) in sympathy.</p><p><strong>Oklo Inc. (NYSE: OKLO) & X-Energy (NASDAQ: XE)</strong></p><p>Nuclear energy developers Oklo (+8%) and X-Energy (+12%) surged following reports that both companies are joining a http://www.streetinsider.com/Hot+List/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html Tue, 21 Jul 2026 16:37:16 -0400 ALK CLDX OKLO PEGA SMCI XE http://www.streetinsider.com/Hot+List/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html <p><strong>After-Hours Stock Movers:</strong></p><p><strong>Super Micro Computer (NASDAQ: SMCI)</strong></p><p>Supermicro shares rocketed 20% higher following a bullish preliminary Q4 fiscal 2026 update. While fourth-quarter revenue is expected near the low end of its $11.0–$12.5 billion guidance, GAAP and non-GAAP gross margins exploded to 15%–17% (nearly doubling the guided 8.2%–8.4%) due to a favorable product and customer mix. Furthermore, record demand drove Q4 new orders above $60 billion, lifting server peers Dell Technologies (+5%) and Hewlett Packard Enterprise (+4.5%) in sympathy.</p><p><strong>Oklo Inc. (NYSE: OKLO) & X-Energy (NASDAQ: XE)</strong></p><p>Nuclear energy developers Oklo (+8%) and X-Energy (+12%) surged following reports that both companies are joining a http://www.streetinsider.com/Hot+List/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html Tue, 21 Jul 2026 16:37:16 -0400 ALK CLDX OKLO PEGA SMCI XE http://www.streetinsider.com/Hot+List/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html <p><strong>After-Hours Stock Movers:</strong></p><p><strong>Super Micro Computer (NASDAQ: SMCI)</strong></p><p>Supermicro shares rocketed 20% higher following a bullish preliminary Q4 fiscal 2026 update. While fourth-quarter revenue is expected near the low end of its $11.0–$12.5 billion guidance, GAAP and non-GAAP gross margins exploded to 15%–17% (nearly doubling the guided 8.2%–8.4%) due to a favorable product and customer mix. Furthermore, record demand drove Q4 new orders above $60 billion, lifting server peers Dell Technologies (+5%) and Hewlett Packard Enterprise (+4.5%) in sympathy.</p><p><strong>Oklo Inc. (NYSE: OKLO) & X-Energy (NASDAQ: XE)</strong></p><p>Nuclear energy developers Oklo (+8%) and X-Energy (+12%) surged following reports that both companies are joining a http://www.streetinsider.com/Hot+List/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html Tue, 21 Jul 2026 16:37:16 -0400 ALK CLDX OKLO PEGA SMCI XE http://www.streetinsider.com/Hot+List/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html <p><strong>After-Hours Stock Movers:</strong></p><p><strong>Super Micro Computer (NASDAQ: SMCI)</strong></p><p>Supermicro shares rocketed 20% higher following a bullish preliminary Q4 fiscal 2026 update. While fourth-quarter revenue is expected near the low end of its $11.0–$12.5 billion guidance, GAAP and non-GAAP gross margins exploded to 15%–17% (nearly doubling the guided 8.2%–8.4%) due to a favorable product and customer mix. Furthermore, record demand drove Q4 new orders above $60 billion, lifting server peers Dell Technologies (+5%) and Hewlett Packard Enterprise (+4.5%) in sympathy.</p><p><strong>Oklo Inc. (NYSE: OKLO) & X-Energy (NASDAQ: XE)</strong></p><p>Nuclear energy developers Oklo (+8%) and X-Energy (+12%) surged following reports that both companies are joining a http://www.streetinsider.com/Hot+List/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html Tue, 21 Jul 2026 16:37:16 -0400 ALK CLDX OKLO PEGA SMCI XE http://www.streetinsider.com/Hot+List/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html <p><strong>After-Hours Stock Movers:</strong></p><p><strong>Super Micro Computer (NASDAQ: SMCI)</strong></p><p>Supermicro shares rocketed 20% higher following a bullish preliminary Q4 fiscal 2026 update. While fourth-quarter revenue is expected near the low end of its $11.0–$12.5 billion guidance, GAAP and non-GAAP gross margins exploded to 15%–17% (nearly doubling the guided 8.2%–8.4%) due to a favorable product and customer mix. Furthermore, record demand drove Q4 new orders above $60 billion, lifting server peers Dell Technologies (+5%) and Hewlett Packard Enterprise (+4.5%) in sympathy.</p><p><strong>Oklo Inc. (NYSE: OKLO) & X-Energy (NASDAQ: XE)</strong></p><p>Nuclear energy developers Oklo (+8%) and X-Energy (+12%) surged following reports that both companies are joining a http://www.streetinsider.com/Hot+List/After-Hours+Stock+Movers%3A+SMCI%2C+OKLO%2C+XE%2C+PEGA%2C+CLDX%2C+ALK/26796147.html Tue, 21 Jul 2026 16:37:16 -0400 ALK CLDX OKLO PEGA SMCI XE http://www.streetinsider.com/FDA/Celldex%27s+barzolvolimab+fails+Phase+2+trial+in+prurigo+nodularis/26795481.html <p>Celldex Therapeutics (NASDAQ: CLDX) reported that its Phase 2 study of barzolvolimab in prurigo nodularis (PN) did not meet its primary or key secondary endpoints, according to a company statement.</p> <p>The study's primary endpoint — the proportion of patients achieving a four-point or greater improvement in the Worst Itch Numeric Rating Scale (WI-NRS) from baseline to Week 12 — was not met at either dose level tested. Secondary measures, including the Investigator's Global Assessment for Chronic Nodular Prurigo score, also failed to differentiate from placebo. No improvement was observed with longer treatment at Week 24.</p> <p>The randomized, double-blind, placebo-controlled study enrolled 140 http://www.streetinsider.com/FDA/Celldex%27s+barzolvolimab+fails+Phase+2+trial+in+prurigo+nodularis/26795481.html Tue, 21 Jul 2026 16:01:27 -0400 CLDX O.31464559 http://www.streetinsider.com/FDA/Celldex%27s+barzolvolimab+fails+Phase+2+trial+in+prurigo+nodularis/26795481.html <p>Celldex Therapeutics (NASDAQ: CLDX) reported that its Phase 2 study of barzolvolimab in prurigo nodularis (PN) did not meet its primary or key secondary endpoints, according to a company statement.</p> <p>The study's primary endpoint — the proportion of patients achieving a four-point or greater improvement in the Worst Itch Numeric Rating Scale (WI-NRS) from baseline to Week 12 — was not met at either dose level tested. Secondary measures, including the Investigator's Global Assessment for Chronic Nodular Prurigo score, also failed to differentiate from placebo. No improvement was observed with longer treatment at Week 24.</p> <p>The randomized, double-blind, placebo-controlled study enrolled 140 http://www.streetinsider.com/FDA/Celldex%27s+barzolvolimab+fails+Phase+2+trial+in+prurigo+nodularis/26795481.html Tue, 21 Jul 2026 16:01:27 -0400 CLDX O.31464559 http://www.streetinsider.com/Press+Releases/Celldex+Reports+Results+from+Phase+2+Study+of+Barzolvolimab+in+Prurigo+Nodularis/26795470.html <ul type="disc"><li><em>Study did not meet key efficacy objectives </em></li><li><em>Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimen</em></li><li><em>Profound systemic mast cell depletion, as evidenced by significant reduction in serum tryptase, observed </em></li><li><em>Phase 3 CSU topline data expected in Sept/Oct 2026; Phase 3 SD and ColdU Enrollment On Track; Phase 2 topline data in AD in late 2026</em></li><li><em>Company to host webcast today at 4:30 pm ET</em><br/><br/></li></ul> <p>HAMPTON, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company’s Phase 2 study of barzolvolimab delivered subcutaneously http://www.streetinsider.com/Press+Releases/Celldex+Reports+Results+from+Phase+2+Study+of+Barzolvolimab+in+Prurigo+Nodularis/26795470.html Tue, 21 Jul 2026 16:01:00 -0400 CLDX O.31464559 http://www.streetinsider.com/Press+Releases/Celldex+Reports+Results+from+Phase+2+Study+of+Barzolvolimab+in+Prurigo+Nodularis/26795470.html <ul type="disc"><li><em>Study did not meet key efficacy objectives </em></li><li><em>Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimen</em></li><li><em>Profound systemic mast cell depletion, as evidenced by significant reduction in serum tryptase, observed </em></li><li><em>Phase 3 CSU topline data expected in Sept/Oct 2026; Phase 3 SD and ColdU Enrollment On Track; Phase 2 topline data in AD in late 2026</em></li><li><em>Company to host webcast today at 4:30 pm ET</em><br/><br/></li></ul> <p>HAMPTON, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company’s Phase 2 study of barzolvolimab delivered subcutaneously http://www.streetinsider.com/Press+Releases/Celldex+Reports+Results+from+Phase+2+Study+of+Barzolvolimab+in+Prurigo+Nodularis/26795470.html Tue, 21 Jul 2026 16:01:00 -0400 CLDX O.31464559 http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Results+from+Phase+2+Study+of+Barzolvolimab+in+Prurigo+Nodularis/26795470.html <ul type="disc"><li><em>Study did not meet key efficacy objectives </em></li><li><em>Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimen</em></li><li><em>Profound systemic mast cell depletion, as evidenced by significant reduction in serum tryptase, observed </em></li><li><em>Phase 3 CSU topline data expected in Sept/Oct 2026; Phase 3 SD and ColdU Enrollment On Track; Phase 2 topline data in AD in late 2026</em></li><li><em>Company to host webcast today at 4:30 pm ET</em><br/><br/></li></ul> <p>HAMPTON, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company’s Phase 2 study of barzolvolimab delivered subcutaneously http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Results+from+Phase+2+Study+of+Barzolvolimab+in+Prurigo+Nodularis/26795470.html Tue, 21 Jul 2026 16:01:00 -0400 CLDX O.31464559 http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Results+from+Phase+2+Study+of+Barzolvolimab+in+Prurigo+Nodularis/26795470.html <ul type="disc"><li><em>Study did not meet key efficacy objectives </em></li><li><em>Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimen</em></li><li><em>Profound systemic mast cell depletion, as evidenced by significant reduction in serum tryptase, observed </em></li><li><em>Phase 3 CSU topline data expected in Sept/Oct 2026; Phase 3 SD and ColdU Enrollment On Track; Phase 2 topline data in AD in late 2026</em></li><li><em>Company to host webcast today at 4:30 pm ET</em><br/><br/></li></ul> <p>HAMPTON, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company’s Phase 2 study of barzolvolimab delivered subcutaneously http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Results+from+Phase+2+Study+of+Barzolvolimab+in+Prurigo+Nodularis/26795470.html Tue, 21 Jul 2026 16:01:00 -0400 CLDX O.31464559 http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Raised+to+%24100+at+Guggenheim/26786900.html (Updated - July 20, 2026 7:14 AM EDT) <p>Guggenheim analyst Yatin Suneja raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $100.00 (from $90.00) while maintaining a Buy rating.</p><p>The analyst commented: "Ahead of the pivotal EMBARQ-CSU1/2 topline readout (n=1,939) expected in 4Q26 (we estimate October), we publish a two-part deep-dive on barzolvolimab's (BIC anti-KIT mAb) probability of success, positioning, and commercial opportunity across chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Base case: efficacy in line with SOC (~35% absolute and ~25% Δ UAS7=0), with consistent response in omalizumab-experienced patients and a similar safety profile as the Phase II http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Raised+to+%24100+at+Guggenheim/26786900.html Mon, 20 Jul 2026 07:14:15 -0400 CLDX http://www.streetinsider.com/Analyst+Comments/Celldex+Therapeutics+%28CLDX%29+PT+Raised+to+%24100+at+Guggenheim/26786900.html (Updated - July 20, 2026 7:14 AM EDT) <p>Guggenheim analyst Yatin Suneja raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $100.00 (from $90.00) while maintaining a Buy rating.</p><p>The analyst commented: "Ahead of the pivotal EMBARQ-CSU1/2 topline readout (n=1,939) expected in 4Q26 (we estimate October), we publish a two-part deep-dive on barzolvolimab's (BIC anti-KIT mAb) probability of success, positioning, and commercial opportunity across chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Base case: efficacy in line with SOC (~35% absolute and ~25% Δ UAS7=0), with consistent response in omalizumab-experienced patients and a similar safety profile as the Phase II http://www.streetinsider.com/Analyst+Comments/Celldex+Therapeutics+%28CLDX%29+PT+Raised+to+%24100+at+Guggenheim/26786900.html Mon, 20 Jul 2026 07:14:15 -0400 CLDX